Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)

被引：0

作者：

Blauvelt, Andrew ^{[1
]}

Thyssen, Jacob P. ^{[2
]}

Guttman-Yassky, Emma ^{[3
]}

Bieber, Thomas ^{[4
]}

Carrascosa, Jose Manuel ^{[5
]}

Simpson, Eric ^{[6
]}

Rosmarin, David ^{[7
]}

Elmaraghy, Hany ^{[8
]}

Meskimen, Eric ^{[8
]}

Natalie, Chitra R. ^{[8
]}

Liu, Zhuqing ^{[8
]}

Xu, Chenjia ^{[8
]}

Pierce, Evangeline ^{[8
]}

Morgan-Cox, MaryAnn ^{[8
]}

Silverberg, Jonathan, I ^{[9
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR 97223 USA

[2] Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark

[3] Icahn Sch Med Mt Sinai, New York, NY USA

[4] Univ Hosp Bonn, Bonn, Germany

[5] UAB, Germans Trias i Pujol Univ Hosp, IGTP, Barcelona, Spain

[6] Oregon Hlth & Sci Univ, Portland, OR USA

[7] Tufts Univ, Sch Med, Boston, MA USA

[8] Eli Lilly & Co, Indianapolis, IN USA

[9] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷

关键词：

monotherapy; atopic dermatitis; moderate-to-severe; lebrikizumab; interleukin (IL)-13;

D O I：

10.1093/bjd/ljac140.018

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

322

引用

页数：2

共 50 条

[1] Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week Results of Two Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trials (ADvocate1 and ADvocate2)
Marquardt, Tzvetelina
Blauvelt, Andrew
Thyssen, Jacob P.
Guttman-Yassky, Emma
Bieber, Thomas
Serra-Baldrich, Esther
Simpson, Eric
Rosmarin, David
Elmaraghy, Hany
Meskimen, Eric
Natalie, Chitra R.
Liu, Zhuqing
Xu, Chenjia
Pierce, Evangeline
Morgan-Cox, MaryAnn
Silverberg, Jonathan
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 61 - 62
[2] Lebrikizumab treatment improves quality of life in patients with moderate-to-severe atopic dermatitis: results from two phase III randomized, double-blinded, placebo-controlled trials (ADvocate1 and ADvocate2)
Lio, Peter
Armstrong, April
Gutermuth, Jan
Nosbaum, Audrey
Sofen, Howard
Casillas, Marta
Pierce, Evangeline
Elmaraghy, Hany
Chen, Sherry
Thyssen, Jacob P.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E109 - E110
[3] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
Blauvelt, Andrew
Thyssen, Jacob P.
Guttman-Yassky, Emma
Bieber, Thomas
Serra-Baldrich, Esther
Simpson, Eric
Rosmarin, David
Elmaraghy, Hany
Meskimen, Eric
Natalie, Chitra R.
Liu, Zhuqing
Xu, Chenjia
Pierce, Evangeline
Morgan-Cox, MaryAnn
Gil, Esther Garcia
Silverberg, Jonathan, I
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (06) : 740 - 748
[4] Efficacy and Safety of Lebrikizumab in moderate to severe atopic Dermatitis: Results of two randomized, double-blind, placebo-controlled phase III Studies (ADvocate1 and ADvocate2) at 52 Weeks
Blauvelt, A.
Thyssen, J. P.
Guttman-Yassky, E.
Bieber, T.
Serra-Baldrich, E.
Simspon, E.
Rosmarin, D.
Diemert, S.
Elmaraghy, H.
Silverberg, J.
ALLERGOLOGIE, 2023, 46 (08) : 530 - 530
[5] Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: Results from Two Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trials
Silverberg, Jonathan
Thaci, Diamant
Seneschal, Julien
Gold, Linda Stein
Blauvelt, Andrew
Simpson, Eric
Chu, Chia-Yu
Liu, Zhuqing
Lima, Renata Gontijo
Pillai, Sreekumar
Guttman-Yassky, Emma
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 62 - 62
[6] Efficacy and safety of lebrikizumab at 16 weeks: pooled analyses from ADvocate1 and ADvocate2 phase III trials in patients with moderate-to-severe atopic dermatitis
Warren, Richard B.
Silverberg, Jonathan I.
Guttman-Yassky, Emma
Thaci, Diamant
Irvine, Alan
Gold, Linda Stein
Blauvelt, Andrew
Simpson, Eric L.
Chu, Chia-Yu
Liu, Zhuqing T.
Lima, Renata Gontijo
Pillai, Sreekumar
Garcia Gil, Esther
Seneschal, Julien
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[7] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: results from two phase III, randomized, double-blinded, placebo-controlled trials
Silverberg, Jonathan I.
Thaci, Diamant
Seneschal, Julien
Gold, Linda Stein
Blauvelt, Andrew
Simpson, Eric
Chu, Chia-Yu
Liu, Zhuqing T.
Lima, Renata Gontijo
Pillai, Sreekumar
Guttman-Yassky, Emma
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E97 - E98
[8] Efficacy of Lebrikizumab in Patients With Atopic Dermatitis and Atopic Comorbidities: Pooled Results From Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)
Sher, Ellen
Boguniewicz, Mark
Golant, Alexandra
Zhong, Jinglin
Atwater, Amber Reck
Dawson, Zach
Siu, Kimberly
De Bruin-Weller, Marjolein
Carrascosa, Jose-Manuel
Thyssen, Jacob
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB148 - AB148
[9] EVOLUTION OF EASI RESPONSE WITH LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO- SEVERE ATOPIC DERMATITIS: POOLED RESULTS FROM TWO PHASE 3 TRIALS (ADVOCATE1 AND ADVOCATE2) AT WEEK 16
Wollenberg, Andreas
Warren, Richard B.
Silverberg, Jonathan I.
Guttman-Yassky, Emma
Thaci, Diamant
Irvine, Alan D.
Gold, Linda Stein
Blauvelt, Andrew
Simpson, Eric L.
Chu, Chia-Yu
Liu, Zhuqing T.
Lima, Renata Gontijo
Pillai, Sreekumar
Gil, Esther Garcia
Seneschal, Julien
ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 53 - 53
[10] Efficacy of Lebrikizumab in Patients with Atopic Dermatitis and Atopic Comorbidities: Pooled Results from 2 Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)
Volc, Sebastian
Sher, Ellen R.
Boguniewicz, Mark
Golant, Alexandra K.
de Bruin-Weller, Marjolein S.
Carrascosa, Jose-Manuel
Zhong, Jinglin
Dawson, Zach
Atwater, Amber Reck
Siu, Kimberly
Thyssen, Jacob P.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 79 - 80

← 1 2 3 4 5 →